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Abstract
Background—Due to the lack of objective tests to diagnose drug induced liver injury (DILI), 
causality assessment is a matter of debate. Expert opinion is often used in research and industry 
but its test-retest reliability is unknown.
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Aims—To determine the test-retest reliability of the expert opinion process used by the Drug-
Induced Liver Injury Network (DILIN)
Methods—Three DILIN hepatologists adjudicate suspected hepatotoxicity cases to 1 of 5 
categories representing levels of likelihood of DILI. Adjudication is based on retrospective 
assessment of gathered case data that includes prospective follow-up information. One hundred 
randomly selected DILIN cases were re-assessed using the same processes for initial assessment 
but by 3 different reviewers in 92% of cases.
Results—The median time between assessments was 938 days (range: 140–2352). Thirty-one 
cases involved >1 agent. Weighted kappa statistics for overall case and individual agent category 
agreement were 0.60 (95% CI: 0.50–0.71) and 0.60 (0.52–0.68), respectively. Overall case 
adjudications were within one category of each other 93% of the time, while 5% differed by 2 
categories and 2% differed by 3 categories. Fourteen-percent crossed the 50% threshold of 
likelihood due to competing diagnoses or atypical timing between drug exposure and injury.
Conclusions—The DILIN expert opinion causality assessment method has moderate inter-
observer reliability but very good agreement within 1 category. A small but important proportion 
of cases could not be reliably diagnosed as ≥ 50% likely to be DILI.
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INTRODUCTION
In 2004, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
established the Drug-Induced Liver Injury Network (DILIN) as a multi-center study with 
aims of improving the understanding of the causes, outcomes and molecular mechanisms of 
hepatotoxicity due to medications or herbal and dietary supplements (HDS)(1). The 
Network of 8 centers has enrolled >1200 patients into the Prospective Study. Cases meeting 
laboratory enrollment criteria are enrolled at the discretion of the investigators at each site 
and based on their clinical suspicion that such abnormalities are at least possibly due to 
DILI. Each case has a clinical narrative and a formatted file of demographics, medications, 
radiography data, histology (when available), and laboratory values in flow sheet format. 
Serum, plasma and DNA are also collected.
Because there are no objective diagnostic tests, DILI remains a diagnosis of exclusion that 
requires adequate clinical, laboratory and imaging data. Scoring algorithms for diagnosis are 
available (2–4) but retest reliability studies are quite limited. Roussel Uclaf Causality 
Assessment Method (RUCAM) that was developed under the auspices of the Council for 
International Organizations of Medical Sciences (CIOMS) is the most widely accepted and 
validated instrument, yet only one study has examined its retest reliability (5). For research 
purposes, DILIN uses a standardized procedure for expert opinion consensus to adjudicate 
the likelihood of DILI that is based in part on RUCAM and yields similar categories of DILI 
likelihood.(6) However, reliability of the DILIN expert opinion process has not been 
critically assessed. Poor reliability would undermine any future mechanistic studies using 
serum, plasma or DNA from the DILIN subjects and undermine the use of DILIN cases for 
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development of other more accessible diagnostic algorithms for the clinician. Therefore, the 
aim of this analysis was to assess the inter-rater, test-retest reliability of the DILIN 
consensus opinion process.
METHODS
DILIN Prospective Cohort
The DILIN study has been previously described in detail.(6) Patients suspected of having 
liver injury due to medications or HDS products were enrolled within 24 weeks of injury 
onset and then followed prospectively for 6 to 24 months depending on the pace and 
completeness of DILI resolution. Because the enrollment window was 24 weeks, cases 
enrolled at varying time points in their DILI event. Enrollment criteria were (1) serum 
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels > 5 times the 
upper limit of the normal (ULN) (or pretreatment baseline if abnormal) on 2 consecutive 
occasions, or (2) alkaline phosphatase (AP) levels > twice the ULN (or pretreatment 
baseline if abnormal) on 2 consecutive occasions, or (3) total serum bilirubin > 2.5 mg/dL, 
or international normalized ratio (INR) > 1.5 with any elevation in serum ALT, AST or AP. 
Cases meeting laboratory enrollment criteria are enrolled at the discretion of the 
investigators at each sight and based on their clinical opinion. Case enrollment is not 
restricted by time of onset because some medications are well known to have very long 
latencies of even years (e.g. nitrofurantoin). We did not restrict enrollment to those with full 
follow-up data showing resolution of injury (i.e. dechallenge) because such restriction would 
hinder the prospective nature of DILIN. We wanted to capture this dechallenge data while 
under study protocol. Injury pattern was categorized as cholestatic (R<2), mixed (R 2–5) or 
hepatocellular (R>5) where R = (ALT/ULN) ÷ (AP/ULN). Severity level was based on INR, 
bilirubin, signs of liver failure, need for hospitalization and fatal or transplant outcome as 
previously described.(6) Exclusion criteria included acetaminophen hepatotoxicity, prior 
liver or bone marrow transplant, alcohol related liver disease, autoimmune hepatitis or 
genetic liver disease. Patients with compensated chronic hepatitis B, C or with nonalcoholic 
fatty liver disease were eligible and enrolled at the discretion of the site investigators. For 
patients with such background liver disease, reviewers used baseline liver enzyme levels, 
viral serologies and viral nucleic acid tests to judge the presence of DILI versus 
exacerbation of underlying liver disease.
At baseline visit, a detailed history was obtained, and clinical, laboratory, and imaging 
results extracted from records. As reported previously, a DILIN protocol battery of tests to 
exclude other causes of liver injury were obtained at enrollment if not extractable from chart 
records (6). Serum, plasma, urine and DNA specimens were sent to a central repository for 
future studies. Subjects were followed for at least 6 months and those with persistent liver 
abnormalities or signs of chronic liver injury were followed through 24 months.
Ninety (90%) of the cases had complete documentation of data for all 21 parameters adapted 
from Agarwal et al. as essential data for DILI cases.(7) (Appendix figure) Nine (9%) were 
missing complete data for one parameter each (4 cases -- incomplete viral serologies, 4 cases 
– no documented hepatic imaging, 1 case -- incomplete ‘washout’ of liver biochemistries); 
one case (1%) was missing complete data for 2 parameters, viral serologies and autoimmune 
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markers. This last case was considered unlikely to be DILI in large part due to lack of these 
data. Overall, the 90 cases with complete data were considered more likely to be DILI than 
the 10 cases with incomplete data (median DILIN scores of 2 versus 3, respectively, p = 
0.04).
DILIN Expert Opinion Process
DILIN causality assessment has been described in detail (6). The process is the same for 
medication and HDS hepatotoxicity, since there is little data to suggest a different causality 
process is necessary or valid. Each case was adjudicated independently by 3 hepatologists 
including the site investigator who enrolled the case. Assessment is based on retrospective 
review of the case history, laboratory data and prospective follow-up study visits. Each 
reviewer assigns a causality score corresponding to percentages of DILI likelihood in which 
1= definite (>95% likelihood), 2 = very likely (75–95%), 3 = probable (50–74%), 4 = 
possible (25–49%), and 5 = unlikely (<25%). Disagreements were identified after the 3 
reviewers submitted their scores. Consensus scores were achieved by electronic mail or 
conference call discussions. Those cases in which agreement could not be reached by the 
three reviewers were then voted upon by one member from each DILIN site during monthly 
conference calls. Final score was assigned by majority vote. For cases involving >1 agent, 
an overall case score and separate individual scores were determined. For example, the 
overall case score might be 1 (definite DILI) with one agent scoring a 2 (very likely causal) 
and the other scoring a 4 (only possibly).
From inception in 2004 to April 16, 2009, adjudication was based upon results obtained 
shortly after enrollment thus simulating the clinician’s task to assess at time of presentation. 
However, when enrollment occurred within in days of onset, data on resolution of injury 
was sparse. After April 16, 2009, the protocol was changed so that adjudication was done 6 
months after enrollment so that follow-up data could be included into the assessment.
Reliability Cohort and Reassessment
The DILIN Data Coordinating Center chose 100 cases by computer driven random 
assignment from the Prospective registry. Two cases involving the interval development of 
new diagnostic information regarding hepatitis E testing were included but the HEV data 
was specifically excluded for reassessment.(8) Chosen cases were stratified 1:1 across April 
16, 2009. Group A included 49 cases enrolled before April 16, 2009, and Group B, 51 cases 
enrolled afterwards. Group A cases did not have 6-month data for the initial assessment but 
these data were available for the reassessment. Group B cases had 6-month data for both the 
initial and reassessments. We stratified across these two periods to examine whether 
reliability is influenced by using follow-up data. For reassessments, 92 cases had 3 new 
reviewers. Due to an administrative error, 8 cases had one previous reviewer and 2 new 
reviewers. No cases were reassessed by the site investigator who enrolled the case. The 
rationale for excluding the enrolling site investigator from reassessments was to minimize 
recall bias as the enrolling investigator is often the hepatologist who continues to care for the 
patient. At least 4 months had to elapse before a case could be selected for reassessment. 
The process of reassessment was otherwise the same.
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Analysis
Standard descriptive statistics were used to characterize this cohort of 100 patients and 
compared to the remaining 983 cases not selected. The original and re-adjudication scores 
were compared for the 100 cases using weighted kappa statistics due to ordinal nature of the 
categories. Because some cases involved >1 drug or HDS product, the reliability at the 
individual agent level was also examined. Weighted kappa statistics were also determined 
for Group A and Group B cases separately. Because the two categories of highest likelihood 
(>95% likelihood and 75–95%), were similar in clinical and research relevance, reliability 
was assessed collapsing these two categories into one thus creating quartiles of percent 
likelihood. Score differences were categorized as 1, 2 or >2 scores apart and direction of 
changes were tallied. Cases with scores crossing the 50% likelihood line (1, 2, or 3 vs. 4 or 
5) were re-examined in detail to assess factors that might have led to such uncertainty in 
DILI diagnosis.
RESULTS
Subjects
Among 1083 DILIN cases adjudicated by June 1, 2011, 49 assessed prior to the use of 6-
month follow-up data (Group A) and 51 assessed with the use of 6-month data (Group B) 
were randomly chosen. These cases were similar to those not chosen across a variety of 
clinical and demographic variables (Table 1). Seventeen of the 100 had initial agreement 
without need for any discussion whatsoever. This rate is similar to the 20.1% for the total 
cohort. Of the 100 cases, 69 involved only one medication or HDS product and 31 involved 
multiple agents. A total of 138 different agents were implicated. The original causality 
scores were similar between Groups A and B (Table 2).
Reliability of the DILIN Expert Opinion Causality Assessment Process
The median time between initial and re-assessment was 938 days (range: 140–2352). Cross 
tabulation of scores between original assessment and re-assessment are shown in Table 2a. 
Weighted kappa statistic for score agreement for overall DILI diagnosis was 0.60, 95% 
confidence interval (CI) 0.50–0.71. Kappa for the 69 single agent cases and 138 individual 
agent scores were similar [0.59 (0.46–0.71) and 0.60 (0.52–0.68)]. Score agreement tended 
to be better for Group B compared to Group A for overall case scores [0.67 (0.38–0.81) vs. 
0.53 (0.38–0.68)], single agent cases [0.69 (0.53–0.85) vs. 0.49 (0.31–0.68)] and individual 
agent scores [0.66 (0.56–0.76) vs. 0.49 (0.34–0.63)], although the differences did not reach 
statistical significance. Collapsing score categories 1 and 2 into one category did not change 
the kappa score for overall case score (0.60 [0.48–0.72]) but the kappa for Group B 
increased to 0.73 (0.59–0.87) while the kappa for Group A fell to 0.44 (0.27–0.61) (Table 
2b). Excluding the 8 cases that had one repeat reviewer on reassessment did not change the 
kappa scores significantly (data not shown).
Magnitude of disagreement
The magnitude of disagreement on reassessment was small. 93% of overall scores were the 
same or differed by only 1 point (92% for Group A; 94% for Group B). (Figure 1a). When 
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scores 1 and 2 were combined into one category, 95 of 100 were within one score (92% for 
Group A; 98% for Group B). (Figure 1b)
Direction of disagreement
Overall causality reassessment scores had a lower likelihood of DILI compared to the initial 
evaluation scores, with a reduction in the average initial score – average reassessment score 
of −0.22 (range 3 to −2). Of the 45 cases where scores differed, 15 were considered more 
likely to be DILI, while 30 were considered less likely to be DILI on reassessment. 
Direction of changes was similar between groups (Group A: 7 more likely, 17 less likely; 
Group B: 8 more likely, 13 less likely; p = ns).
Because there were more cases originally scoring 1–2 (62%) than 4–5 (19%) reflecting the 
careful consideration of other potential causes for liver injury before enrollment, the DILIN 
cohort was prone to a ceiling effect. Therefore we looked at cases originally scoring in the 
middle as well as proportionate increases versus decreases in the reassessment scoring of 
cases originally scoring a 2 or 4 respectively. Cases initially scored as a 3 still tended to 
score less likely to be a DILI event (42% vs. 32%), and cases originally scoring 2, were 
reassessed as less likely to be DILI proportionately more often than cases scoring 4 were 
reassessed as more likely (33% versus 20%). (Table 3)
Cases crossing the 50% likelihood on reassessment
There were 14 (14%) cases with scores that crossed the 50% likelihood threshold on re-
assessment (scores 1–3 vs. 4–5). Eight cases were from Group A and 6 from Group B (p = 
ns). In these 14 cases, 12 scores crossed below the 50% threshold while only 2 crossed the 
line toward more likely DILI (Table 4). Nine of 14 (64%) differed by one point only (i.e. 
between 3 and 4), but 5 differed by >1 point. Eleven involved only one drug or HDS 
product. No implicated agents appeared more than once in these 14 cases. Although not 
statistically significant (p = 0.51), the reassessment score differed from the site 
investigator’s initial assessment score more often (12 of 14) than it did for the other two 
initial reviewers (9 of 14 for both).
Review of these 14 cases and recorded comments by reviewers suggest two major reasons 
for diagnostic uncertainty. Four cases had uncertain or inconsistent timing between agent 
exposure and liver injury, 7 had competing diagnoses and 1 had both reasons (Table 5).
DISCUSSION
The DILIN expert opinion process for causality assessment has moderate test-retest 
reliability on a 5-point scale of likelihood, but agreement within one category of likelihood 
was very good at 93% of cases. Inclusion of 6-month follow-up data tended to improve 
concordance, suggesting diagnostic reliability probably improves when longer follow-up is 
available. These data are critical in establishing the DILIN registry as a source of tissue and 
serum for mechanistic studies. These data also help establish the registry as a reliable source 
of cases for the development of diagnostic instruments that are clinically accessible. While 
consensus expert opinion may be a reliable diagnostic method, it is cumbersome, 
inaccessible to the clinician and used only for research purposes. Development of a 
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computerized diagnostic tool for clinicians will need large registries of reliably diagnosed 
cases.(9)
The reliability of the DILIN consensus process is better than that reported for individual 
assessments without consensus. Studies of reliability between individuals diagnosing 
adverse drug reactions of all types yield kappa statistics as low as 0.05 to 0.2. The consensus 
process used by DILIN substantially elevates the inter-rater reliability (kappa 0.60). The 
consensus of 3 reviewers per case attenuates individual biases and variations in experience. 
Moreover, the collective experience and expertise of the larger causality committee (15–25 
hepatologists per call) is brought to bear on cases where the 3 reviewers cannot agree. Thus, 
the consensus process elevates the test-retest reliability to a level comparable to that reported 
for histologic liver diagnoses that also rely on consensus expert opinion. Chronic viral 
hepatitis biopsies reviewed by 4 expert liver histopathologists produced kappa statistics for 
disease activity and fibrosis of 0.43 and 0.59 respectively.(10) Similar reliability results 
were observed for the histologic diagnosis of NASH (kappa of 0.61).(11) Therefore, if DILI 
diagnosis by expert opinion is to be considered as reliable as interpretation of liver biopsies, 
our data suggest that a rigorous consensus process must be incorporated.
Reliability measured by weighted kappa and percent agreement within one score were 
consistently better in Group B for overall case and individual agent scores, although the 
differences did not reach statistical significance probably due to small sample size. Group 
A’s lack of requirement of 6-month follow-up data is a significant handicap since most 
medical diagnoses become more reliable over time. In addition, operational variability 
probably decreased over time as the DILIN reviewers became more familiar with the scoring 
scale and consensus process. For these reasons, Group B more accurately reflects the 
DILIN’s current reliability. When categories 1 and 2 were combined, the kappa for Group B 
improved to 0.73 with 98% of case reassessments being within one score of each other.
Cases originally scoring in the middle of the scale at 3 were most likely to have different 
scores on reassessment (Table 4) probably due to less certainty of DILI diagnosis as well as 
being midway in a 5-point scale. Reassessment scoring tended to decrease as opposed to 
increase in likelihood of DILI (Table 4). Exclusion of the enrolling site investigator from 
reassessment may have contributed to this finding, because the site investigator was often 
the hepatologist who also provided clinical care to the patient. Such firsthand knowledge of 
the case may provide more accurate causality assessment and thereby provide the site 
investigator a stronger position from which to advocate for a particular score during 
discussions. Nevertheless, the consensus process is robust enough to still produce reasonable 
kappa values and very close agreement within one score without firsthand knowledge of the 
cases on reassessment.
As with any diagnostic tool, DILIN expert opinion is prone to interval discoveries. Recently 
a small percentage of DILI cases were discovered to have evidence of acute hepatitis E virus 
(HEV) infection. (8, 12). Two patients included in this study had data on hepatitis E 
infection discovered between the two assessments. For studying retest reliability of the 
DILIN processes only, we expunged this HEV data from the documents reviewed by the 
second set of reviewers. However, accuracy mandates that such interval discoveries be 
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continually incorporated and cases reassessed as were done for the DILIN HEV cases.(8) 
This reassessment process and updating of scores is built into the DILIN protocol. Concerns 
over such changes should not halt efforts to accrue cases and model diagnostic instruments 
using the DILIN registry for training and validation purposes. Ideally, any new diagnostic 
models for clinicians should be malleable enough to incorporate new discoveries as they 
become available.
DILIN cases vary in complexity particularly in regards to whether or not competing causes 
of liver injury are identified. The 14 (14%) cases that could not be reliably diagnosed as 
DILI with at least 50% certainty (i.e. cases crossing between 3 and 4 on reassessment) were 
some of the more complicated cases that had equivocal presenting diagnostic or longitudinal 
data. Because these complex cases are a part of clinical practice, a detailed examination of 
them may guide the building of an accessible diagnostic instrument for clinicians. None of 
these 14 cases involved isoniazid (INH) or amoxicillin-clavulanate though these drugs were 
the two most frequently implicated in the DILIN registry accounting for >15% of all cases.
(13) The well-established signature patterns of injury for these agents (14–16) probably 
make DILI easier to adjudicate on one side or the other of the 50% threshold. Giving more 
weight to such signature presentations may improve the reliability of future diagnostic 
algorithms.
An alternative cause of liver injury was identified in 10 of the 14 cases and many of these 
alternative diagnoses lack objective, confirmatory tests (e.g. ischemic hepatitis, alcohol-
related liver injury). Alternative diagnoses are well known to complicate attribution of a 
liver injury to a specific medication or herbal product.(17–18) Incorporation of diagnostic 
criteria for competing disorders (e.g. International Autoimmune Hepatitis Group diagnostic 
criteria (19) in expert opinion and future causality instruments may improve reliability in 
such cases. Expert opinion struggled with missing of precise data on timing of liver enzyme 
abnormalities and agent exposure in 5 cases. Perhaps, clear-cut timing of agent start and stop 
and enzyme elevation should be a minimum requirement for assessment akin to minimum 
requirements suggested for DILI case reporting.(20) Rare or unknown hepatotoxicity may 
have contributed to uncertainty in 2 cases (ranitidine and an experimental agent), so it would 
be useful to have standardized scoring of published data that is more precise than what is 
found in RUCAM. The LiverTox on-line textbook developed by the NIDDK, National 
Library of Medicine, and DILIN contains an extensive listing of publications related to DILI 
attributed to several hundred agents (http://livertox.nih.gov/index.html). This site may prove 
useful in standardizing assessment of published data on a particular agent.
Progress in the prevention, early detection and treatment of DILI will require well-
characterized and prospectively followed cases of injury attributed to specific agents. Only 
with large registries of reliably diagnosed DILI will progress be made in determining the 
molecular mechanisms of DILI. This analysis suggests that the expert opinion causality 
assessment process used in DILIN will provide a cohort in whom the majority of cases are 
reliably diagnosed as DILI or not. Specifically, the updated and now well-practiced causality 
assessment process yields moderate diagnostic reliability based on kappa statistics and 
excellent agreement within one score.
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While such internal reliability is encouraging, external reliability amongst non-DILIN 
experts using the same consensus process would be worth examining. The DILIN 
experience is limited to the U.S., and therefore applicability to other countries is unclear. 
The DILIN expert opinion process also lacks quantitative scores of individual characteristics 
that may always hinder retest reliability Importantly, our study does not address the daunting 
problem of validity since there is no gold standard for the diagnosis of DILI. Some have 
suggested using the RUCAM followed by expert opinion in a two-step process to enhance 
reliability and validity.(21)
Finally, a minority of cases straddles the 50% likelihood line and eludes a reliable diagnosis 
of DILI versus not DILI usually because of lack of typical presentation, imprecise 
information on timing or the presence of competing causes of liver injury. Cases scoring in 
this middle range in general, but particularly when concerns over timing or competing 
diagnoses are raised, will need to be reviewed carefully if used for mechanistic studies and 
deserve special attention if a more automated and widely accessible causality assessment 
instrument is to be developed.
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Figure 1. 
Magnitude of differences between original and reassessment scores expressed as 
percentages of cases with 0, 1, 2 and 3 point differences. There were no cases differing by 4 
points. Groups A and B shown separately. (a) Percentages for the 5-point likelihood scoring 
scale. (b). Percentages for a 4-point likelihood scoring scale that combines scores 1 and 2.
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Figure (Appendix). 
Completeness of data at adjudication for parameters adapted from Agarwal et al.(7)
* laboratory values including liver biochemistries, INR, cell count at onset and enrollment
**complete viral serologies for acute hepatitis A, B and C
^ autoimmune serologies (ANA, ASMA)
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Table 1
Features of DILIN cases randomly selected for reassessment compared to cases not reassessed.
Characteristic
Cases Reassessed
N=100
Cases Not Reassessed
N=983 p-value
Demographics:
Age
    Mean (SD) 50.0 (18.59) 48.8 (17.01) 0.41
Gender
    Female 63 (63.0%) 558 (56.8%) 0.24
Race (self report)
    Caucasian 78/100 (78.0%) 764/973 (78.5%)
    Black 12/100 (12.0%) 113/973 (11.6%) 0.96
    Asian 3/100 (3.0%) 36/973 (3.7%)
    Other/Multiracial 7/100 (7.0%) 60/973 (6.2%)
Body mass index (BMI)
    number w/ BMI 88 917
    Mean (SD) 27.0 (6.89) 27.4 (6.50) 0.39
Liver Injury
Categorized Days from Primary Drug Start to DILI Onset
    <= 1 week 7/88 (8.0%) 81/813 (10.0%)
    2 to 4 weeks 29/88 (33.0%) 255/813 (31.4%)
    5 to 12 weeks 26/88 (29.5%) 272/813 (33.5%) 0.84
    13 to 24 weeks 11/88 (12.5%) 85/813 (10.5%)
    > 24 weeks 15/88 (17.0%) 120/813 (14.8%)
# of concomitant drugs in the 2 months prior to DILI onset
  0 to 2 24/93 (25.8%) 191/824 (23.2%)
  3 to 5 25/93 (26.9%) 223/824 (27.1%) 0.83
  > 5 44/93 (47.3%) 410/824 (49.8%)
Pattern of liver injury at onset or earliest after onset*
      Cholestatic (R < 2) 25/100 (25.0%) 248/974 (25.5%)
      Mixed (R 2–5) 17/100 (17.0%) 207/974 (21.3%) 0.59
      Hepatocellular (R > 5) 58/100 (58.0%) 519/974 (53.3%)
Peak values between DILI onset and 6 mo. after enrollment
    ALT (U/L)
      Mean (SD) 1118 (1887) 998 (1481) 0.90
    Alkaline Phosphatase (U/L)
      Mean (SD) 390 (381) 410 (418) 0.33
    Total Bilirubin (mg/dL)
      Median (25th,75th) 9.0 (1.7, 22.9) 9.7 (2.7, 19.5) 0.94
    INR
      Mean (SD) 2.1 (2.49) 1.6 (1.41) 0.07
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Characteristic
Cases Reassessed
N=100
Cases Not Reassessed
N=983 p-value
Adjudication
  Overall causality score
    Definite Greater than 95% 23/100 (23.0%) 173/744 (23.3%)
    Very likely 75–95% 39/100 (39.0%) 312/744 (41.9%)
    Probable 50–75% 19/100 (19.0%) 141/744 (19.0%) 0.22
    Possible 25–50% 10/100 (10.0%) 91/744 (12.2%)
    Unlikely Less than 25% 9/100 (9.0%) 27/744 (3.6%)
Outcomes
  DILIN severity score(6)
    Mild 23/100 (23.0%) 185/744 (24.9%)
    Moderate 19/100 (19.0%) 156/744 (21.0%)
    Moderate-hospitalized 35/100 (35.0%) 221/744 (29.7%) 0.36
    Severe 12/100 (12.0%) 129/744 (17.3%)
    Fatal 11/100 (11.0%) 53/744 (7.1%)
*
R = (ALT/ULN) ÷ (AP/ULN)
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Table 3
Direction of score changes on reassessment stratified by original score.
Original Score N Less likely
DILI
More likely
DILI
No change
1 23 35% NA* 65%
2 39 33% 10% 57%
3 19 42% 32% 26%
4 10 10% 20% 70%
5 9 NA* 33% 67%
*NA = not applicable
Liver Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Hayashi et al. Page 19
Ta
bl
e 
4
A
ge
nt
s, 
sc
or
es
 a
nd
 c
au
se
s f
or
 D
IL
I d
ia
gn
os
is 
un
ce
rta
in
ty
 in
 c
as
es
 c
ro
ss
in
g 
th
e 
50
%
 li
ke
lih
oo
d 
th
re
sh
ol
d 
on
 re
as
se
ss
m
en
t.
#
A
ge
nt
s
In
iti
al
Sc
or
e
R
ea
ss
es
sm
en
t
Sc
or
e
Po
te
nt
ia
l R
ea
so
ns
 fo
r 
D
IL
I D
ia
gn
os
is 
U
nc
er
ta
in
ty
1
R
an
iti
di
ne
2
4
Ti
m
in
g
Co
m
pe
tin
g 
di
ag
no
sis
Sh
or
t l
at
en
cy
 (2
 da
ys
)
Ch
ol
ed
oc
ho
lit
hi
as
is
2
D
ul
ox
et
in
e
1
4
Co
m
pe
tin
g 
di
ag
no
sis
B
ili
ar
y 
ob
str
uc
tio
n
3
To
pi
ra
m
at
e
2
5
Co
m
pe
tin
g 
di
ag
no
sis
H
ep
at
iti
s C
, a
cu
te
4
Ce
fu
ro
xi
m
e/
N
ys
ta
tin
3
4
Co
m
pe
tin
g 
di
ag
no
sis
A
ut
oi
m
m
un
e 
he
pa
tit
is
5
Ce
ph
al
ex
in
/L
ev
of
lo
xa
ci
n
3
5
Co
m
pe
tin
g 
di
ag
no
sis
H
ep
at
iti
s C
, c
hr
on
ic
6
Ex
pe
rim
en
ta
l a
ge
nt
4
3
Co
m
pe
tin
g 
di
ag
no
sis
Is
ch
em
ic
 h
ep
at
op
at
hy
7
Ez
et
im
ib
e/
Si
m
va
sta
tin
3
4
Co
m
pe
tin
g 
di
ag
no
sis
O
cc
ul
t a
lc
oh
ol
8
Su
lfa
m
et
ho
xa
zo
le
-T
rim
et
ho
pr
im
2
4
Ti
m
in
g
U
nc
le
ar
 ti
m
in
g 
fro
m
 d
ru
g 
ex
po
su
re
 to
 e
le
va
te
d 
liv
er
 e
nz
ym
es
9
Ce
ftr
ia
xo
ne
/A
m
pi
ci
lli
n-
Su
lb
ac
ta
m
/F
lu
co
na
zo
le
3
4
Co
m
pe
tin
g 
di
ag
no
sis
Is
ch
em
ic
 h
ep
at
op
at
hy
; o
cc
ul
t a
ce
ta
m
in
op
he
n 
ov
er
do
se
10
Ci
pr
of
lo
xa
ci
n
4
3
Co
m
pe
tin
g 
di
ag
no
sis
H
ep
at
iti
s, 
at
yp
ic
al
 v
ira
l (
gia
nt 
ce
ll)
11
H
yd
ro
xy
cu
t T
M
 
(H
DS
*
)
3
4
Ti
m
in
g
Lo
ng
 la
te
nc
y 
(ap
pro
xim
ate
ly 
75
 da
ys
) a
fte
r s
top
pin
g a
ge
nt
12
A
zi
th
ro
m
yc
in
3
4
Co
m
pe
tin
g 
di
ag
no
sis
Is
ch
em
ic
 h
ep
at
op
at
hy
; o
cc
ul
t a
ce
ta
m
in
op
he
n 
ov
er
do
se
13
U
ltr
a 
V
ita
lit
y T
M
 
(H
DS
*
)
3
4
Ti
m
in
g
Lo
ng
 la
te
nc
y 
(ap
pro
xim
ate
ly 
21
90
 da
ys
) w
hil
e o
n a
ge
nt
14
6-
M
er
ca
pt
op
ur
in
e
3
4
Ti
m
in
g
U
nc
le
ar
 ti
m
in
g 
fro
m
 d
ru
g 
ex
po
su
re
 to
 e
le
va
te
d 
liv
er
 e
nz
ym
es
*
H
er
ba
l D
ie
ta
ry
 S
up
pl
em
en
t
Liver Int. Author manuscript; available in PMC 2016 May 01.
